secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001213900-24-020389
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell amends supply agreement: Re-Tain deal terminates Nov 30, 2024 if FDA not approved
--------------------------------------------------------------------------------

- Agreement auto-terminates on Nov 30, 2024 unless FDA approval for Re-Tain is received by then.
- New payment terms: 75% invoiced monthly during production; 25% final balance on dispatch after FDA OK.
- If no FDA approval by Nov 30, 2024, final balance is invoiced and agreement expires.
- Updated Schedule 7 projects ~160,000 commercial units with expiration 4Q25-1Q26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024020389/0001213900-24-020389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024020389/ea0201306-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-020389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer